13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

Pfizer PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
  • It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity.
  • In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers.
  • Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 19.87 FCF 6.39% Buyback -0.26%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Fairfax Financial Prem Watsa 1.4% $27.8M 2026-03-31
Kahn Brothers Group 2.4% $13.6M 2026-03-31

Recent trading changes over the last 1 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 1 13F filing periods
Net reducers 4 Last 1 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $2.8M Estimated from net added shares
Reduction amount $239.4M Estimated from net reduced shares
Net share change / base shares -74.3% -9,748,538 / 13,112,629
Fairfax Financial Prem Watsa 1 filing periods
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 11.2% 13F value change +$5.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 890,900 Last 1 periods +100,000 (+11.2%) Total shares 990,900 Value $27.8M
Kahn Brothers Group 1 filing periods
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -12.5% 13F value change -$182,053
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 553,950 Last 1 periods -69,217 (-12.5%) Total shares 484,733 Value $13.6M
Gotham Asset Management Joel Greenblatt 1 filing periods
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -40.5% 13F value change -$15.7M
Settlement As of 13F 2025-12-31 · Filed 2026-02-17
Base shares 1,472,086 Last 1 periods -596,382 (-40.5%) Total shares 875,704 Value $21.8M
Starboard Value Jeff Smith 1 filing periods
13F 2025-09-30 Filed 2025-11-14
Sold out Shares -100.0% 13F value change -$207.1M
Settlement As of 13F 2025-09-30 · Filed 2025-11-14
Base shares 8,542,149 Last 1 periods -8,542,149 (-100.0%) Total shares 0 Value $0
Bridgewater Associates Ray Dalio 1 filing periods
13F 2025-06-30 Filed 2025-08-13
Major reduction Shares -38.8% 13F value change -$17.4M
Settlement As of 13F 2025-06-30 · Filed 2025-08-13
Base shares 1,653,544 Last 1 periods -640,790 (-38.8%) Total shares 1,012,754 Value $24.5M

Recent mentions

No public mentions.